FAQ

Answers for
Founders & Co-investors

Clear answers on what we invest in, how our decision process works and how we support founders after the round. Written for founders, co-investors and partners who are considering working with Aegis Capital.

1. Investment Profile & Criteria

At what stage should startups approach you?

We invest at the pre-seed and seed stages. The ideal time to reach out is when:

  • You have a working MVP or an early-stage product.
  • You are already talking to your first customers (or have acquired some).
  • You understand the problem you are solving — and can demonstrate that it exists.

What level of market or technological validation do you expect from a startup?

We do not require revenue, but we need to see evidence that the problem is real and worth solving.

Which projects or industries fall outside your investment focus?

We do not invest in:

  • Businesses without the potential for national or global scalability (e.g., restaurants, local services, traditional retail).
  • Real estate and property development projects.
  • Companies without a technological component or intellectual property (IP).
  • Pure crypto projects or financial speculation without a genuine product layer.

We are also subject to restrictions imposed by the PFR Starter program and therefore cannot invest in certain regulated or excluded sectors, including defense, tobacco, and gambling.

What is your typical investment ticket size?

Our initial investment is typically up to PLN 3 million, with the possibility of follow-on investments bringing the total commitment up to PLN 8 million.

2. Process & Decision-Making

How and where should we submit our pitch deck?

The best way is to send it by email to: aegis@aegiscap.vc

What does your decision-making process look like, and how long does it usually take?

From the first email to a signed term sheet, the process typically takes 6–8 weeks. We have completed investments in as little as 3 weeks, and some have taken up to 12 weeks.

We do not intentionally prolong the process — if we are interested, we move forward without unnecessary delays.

What does the process look like from first contact to closing the round?

Application → Initial Response → Introductory Call → Partner Meeting → Preliminary Due Diligence → Term Sheet → Legal Documentation / Investment Committee

3. Round Structure & Co-Investments

Does Aegis Capital always act as the lead investor?

In most rounds, we act as the lead investor — negotiating terms and coordinating the round.

In selected cases, we may participate as a co-lead or smaller investor, particularly when there is a strong lead investor whom we know and trust.

Do you participate in follow-on rounds?

Yes.

Do you co-invest with angel investors?

Yes.

Do you invest exclusively in Polish companies, or do you also consider international structures?

Our primary focus is on companies with a Polish core — either incorporated in Poland or operating with a main team based in Poland.

We assess international structures on a case-by-case basis.

4. Founder Support & Exit Strategy

What support can founders expect beyond capital?

We are a hands-on fund when it matters, but we do not interfere unnecessarily. We get involved where we can genuinely add value:

Fundraising

  • Introductions to Series A investors in Poland and internationally.
  • Relationships with funds across CEE and Western Europe.
  • Support with fundraising narratives and investor materials.

Network Access

  • Introductions to potential customers, strategic partners, and industry experts through our portfolio and investor network.

Operational Support

  • Guidance on finance, legal matters, and go-to-market strategy, either directly or through trusted partners.

PFR Ecosystem

  • As a portfolio company of a PFR Starter-backed fund, founders gain access to the broader PFR ecosystem, initiatives, and support programs.

We are not consultants — but when you call, we answer.

What is your approach to exit strategy?

Our fund horizon is typically 4–8 years, but we think about exit opportunities from day one.

We do not favor a single exit path. Realistic scenarios include:

  • Strategic Acquisition — sale to a larger industry player (the most common outcome within our investment profile).
  • Secondary Sale — sale of shares to a growth-stage investor during a later financing round.
  • IPO — in exceptional cases involving mature, high-growth companies.

Exit-related provisions such as drag-along rights, tag-along rights, and pre-emption rights are discussed openly at the term sheet stage — with no surprises later in the process.

Healthcare VC

Healthcare VC is venture capital with an extra layer of clinical, regulatory and market-access scrutiny on top of standard investment analysis. Aegis Capital is a HealthTech & Longevity VC built around exactly that discipline. Ageing populations and the digital build-out of health systems are turning HealthTech into one of the most investable categories in Europe — and one of the hardest to back well.

What is Healthcare VC, and how does it differ from generic venture capital?

Healthcare VC funds companies building technology for health systems, patients and clinicians, and accepts the regulatory and clinical complexity that comes with it. Generic VC can move on a strong team and a working MVP; a healthcare-focused investor also asks how the product will meet MDR and FDA requirements, how it will be reimbursed, and how it integrates with clinical workflows. Regulatory risk in healthcare sits well above the classic tech market, so legal and compliance strategy is part of the analysis from the first conversation.

In addition, investing in the sector demands a comprehensive view of how digital health tools improve patient care across the patient life cycle — from the seed stage through later funding rounds.

Aegis Capital is a specialised HealthTech & Longevity VC. As health investors, we use a combined product-and-evidence lens on every company from day one.

Our investment thesis: HealthTech and longevity VC

Aegis Capital invests across six focus areas, set out below, which we revisit as the science and the market move. Longevity is one of the strongest entry points, because it rests on durable shifts — ageing demographics, rising chronic-disease load, and the move of care from hospitals to clinics and homes. We invest directly in operating companies — not in other funds. Recent venture capital in health has concentrated on digital health — telemedicine, mobile tools and wearables — and on biotech tackling diseases such as cancer and Alzheimer's; our model shifts the focus to the next wave of investment in health and longevity technologies.

We invest in startups developing solutions that address unmet medical needs across healthcare and longevity and improve healthy lifespan. Those six focus areas — the sectors where we have the deepest track record — are:

  • AI and Digital Health — AI-driven and tech-enabled services in healthcare
  • Nutritech — innovations in functional food and personalised nutrition
  • Digital Therapy & Mental Health — technology-driven therapeutic solutions improving mental well-being, wellness and access to care
  • Diagnostics — technology-enhanced automation and early disease detection
  • Human Improvement — enhancing health, performance, and quality of life through innovation
  • …and beyond — we welcome new approaches and future-facing ideas in health innovation

What we look for in a healthcare startup

We evaluate healthcare startups against four critical pillars in parallel: clinical evidence, regulatory pathway, market access, and team — with business scalability the thread that runs through all of them. A working prototype is a good starting point. Beyond it, we look for early evidence that the technology addresses a real health problem and is protected by strong, unique IP, plus clarity on how a medical device will be classified under MDR/FDA, how an algorithm will be treated under the AI Act, what reimbursement pathway is realistic, and which clinicians have already engaged with the product. Our medical and financial experts review clinical results, the patent position and the addressable market, because a startup needs a large, high-demand market in place to return a fund.

Founder-first means we support the team with our advice, experience, and network rather than handing over a checklist — so the diligence questions sharpen the plan even if we never invest. If you are building an early-stage HealthTech or Longevity company in CEE, get in touch with our team.

How investing in early-stage healthcare companies works in practice

At Aegis Capital, funding starts with an initial investment of up to PLN 3M per company, with follow-on capacity as companies hit clinical and commercial milestones. Investments in the medical sector are rarely handed over in full at the start; later tranches are tied to reaching those milestones. Total investment per portfolio company can reach PLN 8M over the fund's life, which gives us room to lead a first round and reserve capital for later steps, such as a Series A.

The fund holds PLN 80M in total capital, with 16 investments planned across 22 investors. Like most venture capital, our horizon is long — typically 4 to 8 years — because health technologies need time and capital to reach the clinic and the market, which is why we stay close through active portfolio management and keep backing companies as they grow.

Beyond the cheque

Beyond capital, founders find more than a cheque and a reporting line. Aegis Capital's team offers expert support on go-to-market, regulatory-pathway choices, and introductions into hospitals, clinicians and pharma partners. We help teams move from product-market fit through launched commercial pilots, backing a company's whole platform — not a single product — across its development. This support is hands-on and comes free of any separate fee — it is part of the partnership, not an add-on.

Building a HealthTech startup is not just about securing funding — it is about being part of an active ecosystem. Aegis Capital grows a network of innovators, industry leaders, and fellow founders, creating opportunities for collaboration, growth, and strategic partnerships across healthcare and wellness:

  • A network of innovators & industry leaders — access to scientists, healthcare experts, and experienced founders driving change in HealthTech.
  • HealthTech community & exclusive events — industry meetups, workshops, and networking organised by the fund.
  • Collaborations & strategic partnerships — synergies with other startups, corporate partners, and research institutions to accelerate your impact.

Our portfolio

Aegis Capital turns science into scalable products. Our first investment was Approxima, which is developing a minimally invasive, catheter-based device for the treatment of tricuspid valve regurgitation — a physiological repair of the valve delivered without open-heart surgery. The second, Inoko Vision, is building an optical device (NeuroFET) that tracks retinal eye movements as an objective biomarker, enabling early screening of neurodegenerative disease such as Alzheimer's and Parkinson's. Both reflect our focus on technologies with a clear, measurable impact on patient outcomes.

Who we back, and how to reach us

Aegis Capital invests in startups based in Central and Eastern Europe, and supports their entry into strategic international markets. Whether you are a founder, investor or partner, reach out to us.

Frequently asked questions about Healthcare VC

What is venture capital in healthcare?

Healthcare VC is venture capital that invests in companies building products for health systems, while accepting the clinical, regulatory and reimbursement complexity of the sector. It usually combines capital with sector-specific support and acts as a long-term partner to healthcare companies. Aegis Capital is one such HealthTech & Longevity VC.

Does Aegis Capital invest in digital health startups?

Yes. Digital health is one of our core areas, and many of the healthcare startups we back build software, devices or platforms that diagnose, treat or monitor disease. We look for tools that drive measurable improvements in patient care and fit real clinical workflows.

How does Aegis Capital support healthcare startups beyond funding?

Beyond the cheque, healthcare startups in our portfolio get hands-on help — go-to-market, regulatory navigation, and introductions into hospitals and pharma — not just a quarterly report. That support is part of the partnership.

Why does Aegis Capital focus on health tech and longevity?

An ageing population, rising chronic disease and tighter health budgets make health tech and longevity two of the most durable opportunities in venture capital. We back companies that drive better outcomes and can scale across the market.

How do founders pitch a healthcare VC like Aegis Capital?

Tailor the pitch to the fund's focus, and lead with the unmet need you solve, hard clinical or commercial evidence, your regulatory plan, and the team. When founders pitch us, the strongest decks pair a clear value proposition with proof that the product improves patient outcomes.

What stage does Aegis Capital fund?

Aegis Capital focuses on early-stage HealthTech and Longevity companies, with an initial investment of up to PLN 3M and follow-on potential. Total support per company can reach PLN 8M across the fund's lifecycle.

How long does a healthcare VC decision usually take?

It depends on the stage and the data room, but a focused process may take a few weeks from a first call to a clear yes or no. We aim to give founders directional input quickly, even when the answer is not an investment.

Glossary

The Vocabulary of
HealthTech & Longevity

Plain definitions of the terms that come up in our diagnosis, our portfolio and our conversations with founders. Written for founders, clinicians and co-investors who need the same words to mean the same things.

Health technology

Health technology is the application of organised knowledge and skills to solve health problems and improve quality of life. The World Health Organization uses the term broadly: it covers medical devices, medicines, vaccines, procedures and the systems that deliver them, not only digital tools.

In everyday business language, health technology (often shortened to HealthTech) usually means newer, technology-driven solutions: diagnostic devices, software for clinicians, remote monitoring, data platforms and tools that help hospitals run more efficiently. Before such solutions reach patients, many of them must meet regulatory requirements, for example as medical devices.

Public payers decide whether to fund a new technology through health technology assessment (HTA), which weighs clinical benefit, safety and cost against existing options. For companies building health technology, this means that technical novelty alone is not enough: the product has to show measurable value for patients and for the health system.

Longevity

Longevity means a long duration of life. In biology and medicine it refers both to lifespan, the total number of years lived, and to healthspan, the number of years lived in good health without serious chronic disease.

Research on longevity focuses on the biological mechanisms of ageing, described in science as the hallmarks of ageing: among them genomic instability, telomere shortening, mitochondrial dysfunction, cellular senescence and chronic inflammation. The aim is to understand which of these processes can be slowed or reversed, and which interventions (drugs, nutrition, physical activity, new therapies) extend healthy life.

Longevity has also become an industry. It includes biotechnology companies developing therapies that target ageing, diagnostic firms measuring biological age and services supporting prevention. The growing number of older people worldwide makes this sector economically important, since extending healthspan reduces the burden of age-related diseases on health systems.

Startup

A startup is a young company created to develop a new product or service under conditions of high uncertainty, with the goal of rapid growth. The entrepreneur and academic Steve Blank describes it as a temporary organisation searching for a repeatable and scalable business model.

What distinguishes a startup from a traditional small business is the ambition to scale. A local service company may stay the same size for years, while a startup tests hypotheses about its market, iterates on its product and seeks a model that can grow quickly with relatively little additional cost. Because of this, startups often operate at a loss in their early years.

Most startups finance their growth with external capital: from founders, business angels, grants and venture capital funds. In health and life sciences, the path is usually longer than in other sectors, as products must pass clinical validation and regulatory approval before they can be sold.

Finance

Finance is the field concerned with managing money: raising it, investing it, lending it and allocating it over time. It rests on a few basic concepts, such as the time value of money, the relationship between risk and return, and liquidity.

The discipline is usually divided into three areas. Personal finance covers the decisions of individuals and households; corporate finance deals with how companies fund their operations and investments; public finance concerns the budgets, taxes and debt of states and local governments. Financial markets, banks, insurers and investment funds connect those who have capital with those who need it.

In the innovation economy, finance determines which ideas get a chance to develop. Equity investors, lenders and public programmes take on different levels of risk, and their choices shape which technologies, including those in medicine, reach the market.

Biotechnology

Biotechnology is the use of living organisms, biological systems or their components to create or modify products and processes. The Convention on Biological Diversity defines it as any technological application that uses biological systems, living organisms or their derivatives for a specific use.

Humans have used biotechnology for thousands of years, for instance in brewing and baking. Modern biotechnology began with genetic engineering in the 1970s; in 1982 human insulin produced by genetically modified bacteria became the first approved medicine made with recombinant DNA. Today the field includes monoclonal antibodies, vaccines, gene and cell therapies, and gene editing tools such as CRISPR.

Biotechnology is often divided by application: red (medical), green (agricultural), white (industrial) and blue (marine). Medical biotechnology is among the most capital-intensive areas of innovation, as developing a new therapy requires years of research and clinical trials.

Digital health

Digital health is the use of digital technologies to improve health and the delivery of health care. The term covers telemedicine, mobile health applications, electronic health records, wearable devices, remote patient monitoring and data analytics, including artificial intelligence.

Digital health changes where and how care is provided. A consultation can take place online, a chronic condition can be monitored at home with sensors, and data from many sources can help clinicians make better-informed decisions. The World Health Organization supports these developments through its global strategy on digital health, emphasising interoperability, data protection and equitable access.

Not every digital health product is regulated in the same way. A wellness app that counts steps is a consumer product, while software that diagnoses or guides treatment is usually a medical device and must meet regulatory requirements. This distinction affects development costs, timelines and the evidence a company has to provide.

Mental health

The World Health Organization defines mental health as a state of mental well-being that enables people to cope with the stresses of life, realise their abilities, learn and work well, and contribute to their community. Mental health is therefore more than the absence of a mental disorder.

Mental disorders, such as depression, anxiety disorders, bipolar disorder or schizophrenia, are common: the WHO estimates that around one in eight people worldwide lives with one. Mental health is shaped by biological factors, life experiences, social and economic conditions and access to support.

Many people with mental health problems do not receive care, often because of stigma, cost or a shortage of specialists. This gap has driven the development of new forms of support, including online therapy, digital tools based on cognitive behavioural therapy and services that make it easier to reach help earlier.

Health care

Health care is the organised provision of services aimed at maintaining or improving health: prevention, diagnosis, treatment, rehabilitation and palliative care. It is delivered by doctors, nurses, pharmacists, therapists and other professionals in clinics, hospitals and, increasingly, at home.

Health care is usually described on three levels. Primary care is the first point of contact, such as a family doctor; secondary care involves specialists and hospitals; tertiary care covers highly specialised treatment, for example transplants or complex surgery. Systems differ in how they are financed, from tax-funded national services to social insurance and private insurance.

Most health systems face the same pressures: ageing populations, a rising number of chronic diseases, staff shortages and growing costs. These pressures create demand for solutions that let health care reach more patients with the same resources, from prevention programmes to digital tools and automation.

Venture capital

Venture capital is a form of private equity financing that funds young, high-growth companies in exchange for a share in their ownership. Investors accept a high risk of failure in return for the possibility that a small number of companies in the portfolio will deliver very large returns.

A venture capital fund is typically raised from limited partners, such as institutions, family offices and wealthy individuals, and managed by general partners who select and support investments. Funds usually have a fixed life of around ten years, invest in successive rounds (pre-seed, seed, Series A and later) and earn returns when portfolio companies are sold or listed on a stock exchange.

Beyond capital, venture investors often provide expertise, contacts and help with recruitment or further fundraising. In specialised fields such as health, investors with clinical, regulatory and industry experience can be particularly valuable, as the path from idea to market is long and complex.

Digital therapeutics

Digital therapeutics are evidence-based therapeutic interventions delivered by software to prevent, manage or treat a medical condition. Unlike general wellness apps, they have a defined clinical purpose and must demonstrate their effectiveness, usually in clinical studies.

Digital therapeutics can be used alone or alongside medicines and other treatments. Examples include programmes based on cognitive behavioural therapy for insomnia or depression, applications supporting the management of diabetes, and tools for treating addiction. Many of them are regulated as medical devices, and some are available only on prescription.

The main challenge for digital therapeutics is reimbursement. Germany was one of the first countries to create a dedicated pathway: under its 2019 Digital Healthcare Act, approved digital health applications (DiGA) can be prescribed by doctors and paid for by statutory health insurance. Other countries are developing similar models.

Disease

A disease is an abnormal condition of an organism that disrupts its normal structure or function and is not caused directly by an external injury. It usually manifests through specific signs and symptoms and has an identifiable cause or mechanism, although for many diseases this cause is only partly known.

Diseases are commonly divided into communicable (infectious) diseases, caused by pathogens and transmitted between people, and noncommunicable diseases, such as cardiovascular disease, cancer, chronic respiratory diseases and diabetes. They can also be classified as acute or chronic, and as genetic, acquired or autoimmune.

Noncommunicable diseases now cause around three quarters of all deaths worldwide, according to the World Health Organization. For this reason, modern medicine focuses increasingly on prevention, early detection and the long-term management of chronic conditions. Diseases are coded according to the WHO International Classification of Diseases (ICD).

Genetic predisposition

Genetic predisposition is an increased likelihood of developing a particular disease based on a person's genetic makeup. It does not mean the disease will certainly develop, but that the risk is higher than in the general population.

Predisposition can result from a single gene variant with a strong effect, such as mutations in the BRCA1 and BRCA2 genes that significantly raise the risk of breast and ovarian cancer. More often, it results from many common variants, each with a small effect; their combined impact can be estimated with polygenic risk scores. Whether a disease appears also depends on lifestyle and environmental factors.

Knowing about a genetic predisposition allows earlier and more frequent screening, preventive measures and, in some cases, targeted treatment. Genetic testing raises ethical questions as well, including privacy, the right not to know and the risk of discrimination, so it is usually accompanied by genetic counselling.

Funding

Funding is the provision of money for a specific purpose, such as starting a company, carrying out a research project or developing a product. It can come from private investors, banks, public institutions, foundations or the organisation's own revenue.

Funding takes different forms. Equity funding means selling a share of the company to investors; debt funding means borrowing money that must be repaid with interest; grants are non-repayable and are often awarded for research and innovation. Startups typically raise funding in rounds, from early rounds based on an idea and a team to later ones based on proven results.

In health innovation, funding often has to cover a long period before any revenue appears, including laboratory work, clinical studies and certification. Combining public grants with private investment is a common way to share this risk.

Research institute

A research institute is an organisation dedicated to conducting scientific research, usually in a defined field. It may operate independently, as part of a university, under a government or as a unit of a company.

Research institutes differ in the type of research they carry out. Some focus on basic research, which expands knowledge without an immediate practical goal; others conduct applied research aimed at solving specific problems or developing new technologies. Their work is financed through public budgets, research grants, partnerships with industry and private donations.

Research institutes are an important source of innovation in medicine and biotechnology. Discoveries made in their laboratories are often commercialised through licensing to companies or by creating spin-off companies, which may then attract investors to bring the technology to patients.

(Human) Improvement

Human improvement, also called human enhancement, refers to the use of technology, medicine or other interventions to improve human abilities beyond what is needed to restore health. It can concern physical, cognitive or emotional capacities, as well as lifespan.

The concept is usually explained by contrasting it with therapy. Therapy restores normal function, for example a hearing aid for a person with hearing loss, while enhancement aims to exceed typical human capacities. In practice the boundary is not always sharp: vaccines, for instance, strengthen the immune system of healthy people. Examples discussed in this context range from cognitive enhancing drugs and wearable exoskeletons to gene editing and brain-computer interfaces.

Human improvement raises important ethical questions, including safety, fairness of access, consent and the effect on what is considered normal. These debates are especially relevant in longevity research, where the goal of extending healthy life sits on the border between preventing disease and enhancing human biology.

Artificial intelligence

Artificial intelligence (AI) is the field of computer science that develops systems capable of performing tasks normally requiring human intelligence, such as recognising patterns, understanding language, making predictions and solving problems. The term was coined by John McCarthy in the proposal for the 1956 Dartmouth workshop.

Most of today's AI is based on machine learning, in which systems learn from data rather than following rules written by programmers. Deep learning, which uses multi-layered neural networks, has enabled major progress in image recognition, speech processing and, more recently, generative models that create text, images and code.

In medicine, AI supports the analysis of medical images, the prediction of disease risk, drug discovery and the automation of administrative tasks. Because errors can affect patients, AI used for medical purposes is regulated: in the European Union it typically falls under the medical device rules and is classified as high risk under the AI Act.

Nutrition

Nutrition is the process by which an organism takes in and uses food to support growth, maintenance and repair of the body. The term also refers to the science studying the relationship between diet, health and disease.

Nutrients are divided into macronutrients (carbohydrates, proteins and fats), which provide energy and building material, and micronutrients (vitamins and minerals), needed in small amounts for many biological processes. Water and dietary fibre also play key roles. Nutritional needs differ with age, sex, physical activity and health status.

Poor nutrition, which includes both undernutrition and overweight or obesity, is a major risk factor for chronic diseases such as type 2 diabetes, cardiovascular disease and some cancers. Nutrition is therefore a key area of prevention, and a growing field of research explores personalised dietary recommendations based on individual biology.

Synergy

Synergy is the interaction of two or more elements whose combined effect is greater than the sum of their separate effects. The word comes from the Greek "synergos", meaning working together.

In pharmacology, synergy occurs when two drugs given together produce a stronger effect than would be expected from adding their individual effects. Combination therapies used in cancer treatment or HIV rely on this principle, which can increase effectiveness and lower the risk of drug resistance. The opposite effect, when one substance weakens another, is called antagonism.

In business, synergy describes the additional value created by combining companies, teams or resources, for example through shared costs, complementary technologies or access to new markets. Expected synergies are often used to justify mergers, acquisitions and partnerships, although in practice they are not always achieved.

Diagnosis

Diagnosis is the process of identifying a disease or condition on the basis of a patient's history, signs, symptoms and test results. The term also refers to the conclusion reached at the end of this process.

A clinician usually begins with a medical interview and physical examination, then orders tests such as blood analyses, imaging or biopsies. Because many conditions share similar symptoms, the clinician considers several possibilities and rules them out step by step; this is called differential diagnosis. The quality of a diagnostic test is described by its sensitivity (how well it detects people who have the disease) and specificity (how well it excludes those who do not).

An accurate and early diagnosis is the basis for effective treatment and often improves the patient's prognosis. New diagnostic technologies, including molecular tests, point-of-care devices and AI-supported image analysis, aim to make diagnosis faster, more precise and more widely available.

Strategic partnership

A strategic partnership is a long-term, formal cooperation between two or more organisations that pursue shared goals while remaining independent. Partners combine resources, knowledge or market access to achieve results that would be difficult to reach alone.

Strategic partnerships can take many forms: joint research and development, licensing agreements, co-marketing, distribution agreements or joint ventures. They are usually based on a contract setting out each party's contribution, the division of costs and benefits, and the rules for intellectual property.

In health care and life sciences, such partnerships are common. Pharmaceutical companies partner with biotechnology firms to access new drug candidates, technology companies cooperate with hospitals to validate solutions in clinical practice, and startups partner with larger players to reach international markets.

Environmental factor

An environmental factor is any external influence on an organism that is not part of its genetic makeup. In health, it includes physical, chemical, biological and social conditions, such as air quality, diet, physical activity, infections, workplace exposures and living conditions.

Environmental factors often interact with genetics. A person may have a genetic predisposition to a disease, but whether it develops can depend on exposures such as smoking, pollution or stress. The concept of the exposome, introduced in 2005, describes the totality of environmental exposures a person experiences from conception onwards.

Many environmental risks can be changed, which makes them a key target of public health. Air pollution alone is linked by the World Health Organization to millions of premature deaths each year, and reducing exposure to harmful factors is one of the most effective ways to prevent chronic disease.

World Health Organization

The World Health Organization (WHO) is a specialised agency of the United Nations responsible for international public health. It was founded on 7 April 1948, a date now marked each year as World Health Day, and is headquartered in Geneva, Switzerland.

The WHO sets international health standards, publishes guidelines, monitors global health trends and coordinates the response to epidemics and health emergencies. It maintains the International Classification of Diseases (ICD) and the list of essential medicines, and it supports countries in strengthening their health systems. Its decisions are made by the World Health Assembly, composed of delegations from member states.

The WHO Constitution contains a widely cited definition of health as a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity. The organisation played a central role in the eradication of smallpox and in coordinating the global response to COVID-19.

Signs and symptoms

Signs and symptoms are the manifestations of a disease or condition. Although the words are often used interchangeably, medicine distinguishes between them: a symptom is something the patient experiences and reports, while a sign is something that can be observed or measured by another person.

Pain, fatigue, nausea and dizziness are examples of symptoms, because only the patient can feel and describe them. Fever measured with a thermometer, a rash, high blood pressure or an abnormal heart sound are signs, because a clinician can detect them objectively. Some features, such as a cough, can be both reported by the patient and observed.

Signs and symptoms are the starting point of diagnosis. A characteristic combination of them, called a syndrome, can point to a specific condition. Some diseases develop without any noticeable symptoms for a long time, which is why screening tests are used to detect them early.

Pathogen

A pathogen is a microorganism or other biological agent that can cause disease in its host. The main groups of pathogens are viruses, bacteria, fungi and parasites; prions, which are misfolded proteins, are also considered infectious agents.

Pathogens cause disease in different ways: by invading and damaging cells, by producing toxins or by triggering an excessive immune response. Their ability to cause disease is called pathogenicity, and the severity of the disease they cause is called virulence. They can spread through the air, water, food, direct contact, body fluids or carriers such as insects.

The immune system is the body's main defence against pathogens, supported by vaccines, antibiotics, antiviral drugs and hygiene. A growing global challenge is antimicrobial resistance, which occurs when pathogens adapt and stop responding to the medicines used to treat them.

Immune system

The immune system is the network of cells, tissues, organs and molecules that protects the body against pathogens and other threats, including cancer cells. It recognises what is foreign or abnormal and works to eliminate it.

The immune system has two main parts. The innate immune system responds quickly and in a general way, through physical barriers such as the skin, inflammation and cells that engulf invaders. The adaptive immune system, based on T cells and B cells, responds more slowly but specifically, produces antibodies and creates immunological memory, which allows a faster response to the same pathogen in the future. This memory is the principle behind vaccination.

When the immune system does not work properly, problems arise: immunodeficiencies make the body vulnerable to infections, while autoimmune diseases occur when it attacks the body's own tissues. With age the immune system gradually weakens, a process called immunosenescence. Therapies that use or modulate the immune system, such as cancer immunotherapy, are among the most important areas of modern medicine.

Screening (medicine)

Screening in medicine is the systematic testing of people who have no symptoms in order to detect a disease, or its risk factors, at an early stage. Its aim is to find conditions when treatment is more effective and outcomes are better.

Examples include mammography for breast cancer, cervical cytology, colonoscopy for colorectal cancer and newborn screening for metabolic disorders. A screening test does not establish a diagnosis: a positive result means that further diagnostic tests are needed. The principles for deciding whether screening makes sense were formulated by Wilson and Jungner for the WHO in 1968 and are still used today.

Screening also has limitations. False positive results can cause anxiety and unnecessary procedures, and some detected abnormalities would never have caused harm, which is called overdiagnosis. For this reason, screening programmes are targeted at groups in which the benefits outweigh the risks, defined for example by age or family history.

Organism

An organism is any individual living entity capable of carrying out the processes of life, such as metabolism, growth, response to stimuli and reproduction. Organisms range from single-celled bacteria to complex multicellular plants and animals, including humans.

Organisms are divided into unicellular, made of a single cell, and multicellular, in which cells specialise and form tissues, organs and organ systems. Biologists classify them into three domains: bacteria, archaea and eukaryotes, the last of which includes animals, plants, fungi and protists. Viruses are not usually considered organisms, because they cannot reproduce outside a host cell.

In biotechnology and medicine, organisms play several roles. Some cause disease, others are used to produce medicines, such as bacteria and yeast producing insulin, and model organisms such as mice, fruit flies and nematodes help scientists study diseases and ageing before research moves to humans.

Technology

Technology is the application of scientific knowledge and skills to practical purposes, especially to create tools, products and processes. The term covers both physical objects, such as machines and devices, and methods and systems, such as software or production techniques.

Technology develops through the interaction of science, engineering and market needs. Some technologies, called general-purpose technologies, affect almost every sector of the economy; examples include electricity, computers, the internet and, increasingly, artificial intelligence. Each wave of such technologies changes the way people work, communicate and receive care.

In health care, technology ranges from diagnostic equipment and surgical robots to electronic records and telemedicine platforms. Its value depends not only on technical performance, but also on safety, ease of use, integration with existing systems and evidence that it improves outcomes for patients.

Innovation

Innovation is the introduction of something new or significantly improved into practice: a product, service, process, business model or form of organisation. The OECD Oslo Manual stresses that an idea becomes an innovation only when it is made available to users or put into use.

Innovation differs from invention. An invention is a new idea or technical solution, while innovation means turning it into something that creates value in practice. The economist Joseph Schumpeter described innovation as the driving force of economic development and the source of "creative destruction", in which new solutions replace old ones. Innovations can be incremental, improving existing solutions, or disruptive, changing a market or sector.

In medicine, innovation includes new drugs, devices, diagnostic methods and models of care. Bringing health innovation to patients usually requires clinical evidence, regulatory approval and acceptance by payers and clinicians, which makes the process longer and more demanding than in many other industries.

Scientist

A scientist is a person who systematically gathers and evaluates knowledge about the natural or social world using the scientific method. The English word was coined by the philosopher and historian of science William Whewell in the 1830s.

Scientists formulate hypotheses, design experiments or observations, analyse data and publish their findings, which are reviewed by other experts in a process called peer review. They work in universities, research institutes, government agencies and companies, and specialise in fields such as biology, chemistry, physics, medicine or computer science.

Scientists are often at the origin of new health technologies. Many biotechnology and medical device companies are founded or co-founded by researchers who want to bring their discoveries out of the laboratory, which requires combining scientific expertise with business skills or partners who have them.

Quality of life

Quality of life is a person's overall sense of well-being, covering physical, psychological, social and material aspects of life. The World Health Organization defines it as an individual's perception of their position in life in the context of the culture and value systems in which they live, and in relation to their goals, expectations, standards and concerns.

In medicine, the narrower concept of health-related quality of life is used. It describes how a disease and its treatment affect a person's daily functioning, symptoms, emotional state and social life. It is measured with standardised questionnaires, such as the EQ-5D or the SF-36, filled in by patients themselves.

Quality of life has become a key outcome in clinical research and health policy. Health economists combine it with survival in the quality-adjusted life year (QALY), which helps compare the value of different treatments. For many chronic conditions, improving quality of life is as important a goal as extending life.

World population

World population is the total number of people living on Earth at a given time. According to the United Nations, it passed 8 billion in November 2022, having doubled since the mid-1970s.

Population growth is slowing as fertility rates fall in most regions of the world. United Nations projections from 2024 indicate that the global population will continue to grow for several decades and peak at around 10.3 billion in the mid-2080s, before beginning to decline slowly. At the same time, life expectancy is increasing, so the share of older people is rising in almost every country.

Population ageing has major consequences for health care and the economy. More people live with chronic diseases, demand for care grows and the number of working-age people supporting each older person falls. These changes increase interest in prevention, healthy ageing and technologies that help health systems serve more patients.

MDR

MDR stands for the Medical Device Regulation, Regulation (EU) 2017/745, which sets the rules for placing medical devices on the market in the European Union. It was adopted in 2017 and has applied since 26 May 2021, replacing the earlier Medical Devices Directive and the Active Implantable Medical Devices Directive.

The MDR introduced stricter requirements than the previous directives. They include tighter rules on clinical evidence, closer supervision of notified bodies, post-market surveillance, a Unique Device Identification (UDI) system and the European database on medical devices (EUDAMED). Devices are divided into risk classes I, IIa, IIb and III, and the class determines the conformity assessment procedure.

The regulation also changed the situation of software: under its classification rules, much medical software now falls into higher risk classes and requires assessment by a notified body. Because of the scale of the changes, transition periods for devices certified under the old rules were extended, depending on the risk class, until the end of 2027 or 2028.

Medical devices

A medical device is any instrument, apparatus, software, implant, material or other article intended by its manufacturer to be used for a medical purpose, such as diagnosing, preventing, monitoring or treating a disease or injury. Unlike medicines, medical devices do not achieve their main effect through pharmacological, immunological or metabolic means.

The category is very broad. It includes simple products such as bandages and syringes, as well as contact lenses, blood glucose meters, pacemakers, imaging equipment, surgical robots and medical software. Regulators group devices into classes according to risk: in the European Union these are classes I, IIa, IIb and III, and in the United States classes I, II and III.

Before a medical device can be sold, the manufacturer must demonstrate its safety and performance. In the European Union this leads to CE marking under the MDR, and in the United States to clearance or approval by the Food and Drug Administration. The higher the risk class, the more clinical evidence and independent assessment are required.

SaMD

SaMD stands for Software as a Medical Device. The International Medical Device Regulators Forum (IMDRF) defines it as software intended to be used for one or more medical purposes that performs these purposes without being part of a hardware medical device.

Examples of SaMD include an application that analyses medical images to detect signs of disease, software that calculates medication doses, or a program that assesses the risk of a heart attack based on patient data. SaMD can run on general computing platforms such as smartphones, computers or the cloud. Software that only controls a physical device, for example the firmware of an infusion pump, is not SaMD but part of that device.

The IMDRF framework assesses the risk of SaMD by two factors: the significance of the information the software provides for a health decision and the seriousness of the patient's condition. In the European Union, SaMD is regulated under the MDR or the IVDR, and in the United States by the FDA. Developers must show both clinical validity and the quality of the software development process.

IVDR

IVDR stands for the In Vitro Diagnostic Medical Devices Regulation, Regulation (EU) 2017/746. It governs devices used to examine samples taken from the human body, such as blood, urine or tissue, and has applied since 26 May 2022, replacing the earlier In Vitro Diagnostic Medical Devices Directive.

In vitro diagnostic devices include laboratory tests, reagents, analysers, home pregnancy tests, genetic tests and software used to interpret results. The IVDR introduced a new risk-based classification with classes A, B, C and D, where D covers the highest-risk tests, for example those used to screen blood donations for serious infections.

The most significant change concerns notified bodies. Under the old directive, most in vitro diagnostic devices could be self-certified by the manufacturer, while under the IVDR the large majority require assessment by a notified body. To avoid shortages of tests, the European Union introduced staggered transition periods for existing devices, depending on their risk class.

‍